T1DType 1 Diabetes
Copyright 1988-2018 AcronymFinder.com, All rights reserved.
References in periodicals archive ?
'Sherron's expertise and extensive clinical development experience will be invaluable as we execute our clinical and regulatory strategy for PRV-031 (teplizumab) for the interception and prevention of T1D.'
These 17 CDN members, along with additional TCOYD applicants from around the world, were selected for their passion and commitment to the T1D community.
The company said Farxiga was recently approved in Europe (5mg) and Japan (5mg, potential up -titration to 10mg) under the name Forxiga, as an adjunct to insulin in adults with T1D.
The trial compared operational performance of the iLet in the insulin-only configuration for one week versus the bihormonal configuration for one week in 10 adult participants with T1D. Trial participants started therapy by entering only their body weight into the device.
Among the T1D participants, 47.5% calculated the number of carbohydrate exchanges they consume experimentally, 47.5% used weight and nutritional tables, and only 5% used weighting method and online dietary diary (Table 2).
The study subjects comprised 121 T1D patients from the Department of Diabetology, Government Rajaji Hospital in Madurai, Tamil Nadu, India, along with 214 their first degree relatives (120 parents and 94 siblings) as controls.
Sotagliflozin, developed by Sanofi SA and Lexicon Pharmaceuticals, has the potential to be the first oral anti-diabetic drug approved in the United States together with insulin therapy to improve glycemic (blood sugar) control in adults with T1D.
Given the importance of diabetes-related family dynamics and parental support, pediatric T1D has been characterized as a family disease (9).
"Diabetes centres all over the world follow different protocols in diabetes management technology," Dr Petrovski, said, adding, "The access to effective T1D treatment and the ease with which patients can use insulin to control the condition depends on that protocol."
Thanks to all of the participating teams, sponsors, and donors for supporting this important cause as we take another step towards improving the lives of millions of Americans through the eventual cure of T1D!
Lawrence Fisher, Ph.D., from the University of California, San Francisco, and colleagues compared the effectiveness of two interventions -- OnTrack, an emotion-focused intervention, or KnowIt, an educational/behavioral intervention -- to reduce DD and improve glycemic control among 301 adults with T1D.
Through his work at Butler Snow, Tray has involvement with The National Diabetes and Obesity Research Institute (NDORI) in Biloxi and T1D connections via his colleagues.